Image For Activity Cover
Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk (JACC Heart Failure September 2024)
Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk

Guideline-directed medical therapy (GDMT) decisions may be less affected by single patient variables such as blood pressure or kidney function and more by overall risk profile. In STRONG-HF (Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure), high-intensity care (HIC) in the form of rapid uptitration of heart failure (HF) GDMT was effective overall, but the safety, tolerability and efficacy of HIC across the spectrum of HF severity is unknown. Evaluating this with a simple risk-based framework offers an alternative and more clinically translatable approach than traditional subgroup analyses.

 

Editors

JACC Heart Failure Editor-in-Chief
Biykem Bozkurt, MD, PhD, FACC 

Deputy Editor
Akshay S. Desai, MD, MPH 

JACC Heart Failure CME/MOC Editor
Kenneth A. Ellenbogen, MD

Author
Jordan Gavin, MD 

Important Dates

Date of Release: September 2, 2024
Term of Approval/Date of CME/MOC Expiration: September 1, 2025

Summary
Availability: On-Demand
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
Android App Download IOS App Download Powered By